Miracor Medical Systems to Release latest clinical data about its PICSO Impulse System at “EuroPCR 2014” next week

Miracor has begun European commercialization of CE-marked PICSO®  as an adjunct to angioplasty in acute STEMI patients

Miracor Medical Systems announced today that clinical data involving a study of its PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) System will be presented from the podium next week at “EuroPCR.” PICSO is designed to improve myocardial perfusion following primary PCI (percutaneous coronary intervention, or angioplasty). Clinical trial data will analyze the impact of the Miracor PICSO technology on infarct size reduction in patients who had received PICSO therapy immediately following angioplasty compared to a historical control group. Additionally the data should confirm the safety profile of the PICSO technology. (Click here for video animation of PICSO®.)
The clinical data will be presented at EuroPCR from the podium on Friday, May 23, by co-investigator Tim P. van de Hoef, MD, FESC, Academic Medical Centre (AMC), University of Amsterdam. “We have been very excited to participate in this trial, and the analysis of the data should be of interest to other colleagues in the cardiovascular space,” said Dr. van de Hoef, a research fellow of Prof. Dr. Jan Piek (AMC), the principal investigator for this trial.
“Impaired microcirculation occurs in nearly one in three severe heart attack patients, and this unacceptable incidence is directly correlated with unwelcome outcomes for patients,” added Ludwig Gold, CEO of Miracor Medical. “PICSO® is designed to ameliorate this life-threatening condition by significantly amplifying the redistribution of blood into the blood-starved myocardium of severe heart attack patients. Clinical data highlighting this major benefit of PICSO® as an immediate follow-on therapy post-angioplasty is being acknowledged by an increasing number of interventional cardiologists throughout Europe.”
The Miracor PICSO® Impulse System is designed to treat acute heart attack STEMI patients in complement with percutaneous coronary intervention (PCI, or coronary angioplasty). ‘STEMI’ is an acronym meaning ST-segment Elevation Myocardial Infarction. Heart attacks are divided into three types, according to their severity. A STEMI heart attack is the most severe type. In a STEMI heart attack, the coronary artery is completely blocked off by the blood clot, and as a result virtually all the heart muscle being supplied by the affected artery starts to become necrotic.
To date, Miracor has raised $15 million in venture capital and another $9 million in public funding. Major investors include Earlybird Venture Capital, Delta Partners and SHS.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.